Publications by authors named "Dillon M Magee"

The neuromuscular electrical stimulation (NMES) parameters that optimally modulate torque output during prolonged stimulation protocols are not well-established. The purpose of this study was to compare torque output between low-frequency and high-frequency NMES protocols while increasing stimulation intensity. Eleven healthy young individuals received a repetitive, intermittent low-frequency (20 Hz) and high-frequency (60 Hz) NMES over the quadriceps muscles.

View Article and Find Full Text PDF

Purpose: Neuromuscular electrical stimulation (NMES) is commonly used in rehabilitation settings to increase muscle mass and strength. However, the effects of NMES on muscle growth are not clear and no human studies have compared anabolic signaling between low-frequency (LF) and high-frequency (HF) NMES. The purpose of this study was to determine the skeletal muscle anabolic signaling response to an acute bout of LF- and HF-NMES.

View Article and Find Full Text PDF

Introduction: Stroke results in limited ability to produce voluntary muscle contraction and movement on one side of the body, leading to further muscle wasting and weakness. Neuromuscular electrical stimulation is often used to facilitate involuntary muscle contraction; however, the effect of neuromuscular electrical stimulation on muscle growth and strengthening processes in hemiparetic muscle is not clear. This study examined the skeletal muscle anabolic response of an acute bout of neuromuscular electrical stimulation in individuals with chronic stroke and healthy older adults.

View Article and Find Full Text PDF
Article Synopsis
  • IL-17A is found to be overexpressed in some lung cancer patients and may encourage tumor growth by enhancing inflammation and suppressing immune responses.
  • Researchers conducted experiments using genetically modified mice to study the effects of IL-17A on lung tumors, finding faster tumor growth and poorer survival rates compared to normal controls.
  • Treatment with antibodies that block IL-6 or deplete neutrophils improved outcomes in IL-17A-expressing tumors, indicating a potential therapeutic strategy for patients with this cytokine's elevation.
View Article and Find Full Text PDF